GB2443928A — Transdermal pharmaceutical composition comprising Zolpidem
Assigned to Tiziana Life Sciences Ltd · Expires 2008-05-21 · 18y expired
What this patent protects
The invention relates to transdermal pharmaceutical compositions containing an imidazo [1,2- a ] pyridine-3-acetamide such as Zolpidem. Compositions comprising an imidazo [1,2- a ] pyridine-3-acetamide and caffeine are also disclosed. Claims to the compositions for treating d…
USPTO Abstract
The invention relates to transdermal pharmaceutical compositions containing an imidazo [1,2- a ] pyridine-3-acetamide such as Zolpidem. Compositions comprising an imidazo [1,2- a ] pyridine-3-acetamide and caffeine are also disclosed. Claims to the compositions for treating disorders including leukoencephalopathy, obsessive compulsive disorder, brain lesions, cerebral infarct, intracerebral bleeding, Ramsay-Hunt syndrome, ischemic brain damage; and conditions involving strabismus, salivation, muscle spasm, impaired swallowing, smell, or taste, are also included. A further independent claim is included for a composition comprising an imidazo [1,2- a ] pyridine-3-acetamide and caffeine.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.